Results 71 to 80 of about 163,713 (265)

Essential Updates 2024–2025: Surgical Strategy for Esophageal Cancer Toward a New Paradigm in the Era of Immunotherapy and Personalization

Annals of Gastroenterological Surgery, EarlyView.
This review summarizes key advances from 2024 to 2025 that are reshaping esophageal cancer surgery toward a strategy‐oriented, personalized paradigm through the integration of immunotherapy, population aging, and intelligent technologies. Adjuvant nivolumab after neoadjuvant chemoradiotherapy remains the only perioperative approach with durable benefit,
Shuichiro Oya, Koichi Yagi, Yoshifumi Baba   +2 more
wiley   +1 more source

Microarray Analysis of Radioresistance-associated Genes in Esophageal Squamous Cell Carcinoma

Zhongliu Fangzhi Yanjiu, 2019
Objective To identify the novel radioresistance-associated genes in esophageal squamous cell carcinoma and build a foundation for the individualized radiotherapy.
ZHU Qingshan, LI Junkuo, LIU Weipeng, MA Tingwei, DAI Ningtao, FENG Lianjie, WEI Tao, ZHOU Fuyou   +7 more
doaj   +1 more source

Extent of Lymph Node Dissection for cStage I Siewert Type I/II Cancers Based on Lymph Node Metastasis Risk Stratification

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aim The optimal surgical strategy and extent of lymph node (LN) dissection for clinical Stage I (cStage I) adenocarcinoma of the esophagogastric junction (AEG) remain controversial. This study aimed to evaluate surgical outcomes and clarify the prevalence and distribution of LN metastasis according to tumor characteristics in cStage I Siewert ...
Masayoshi Terayama, Akihiko Okamura, Tomoyuki Irino, Naoki Takahashi, Jun Kanamori, Yu Imamura, Masaru Hayami, Motonari Ri, Souya Nunobe, Masayuki Watanabe   +9 more
wiley   +1 more source

Design and Application of Nanozymes: Current Trends and Cutting‐Edge Breakthroughs

Advanced Science, EarlyView.
Kelong Fan, Hui Wei, Xiyun Yan
wiley   +1 more source

Optimal Indication of D3 Lymph Node Dissection for Non‐Metastatic Colon Cancers by Tumor Stages: Evaluation of Therapeutic Value Index for Each Lymph Node Station

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Aims To explore the therapeutic impact of D3 lymph node dissection for non‐metastatic colon cancers, evaluating the therapeutic value index for each lymph node station according to surgical stages. Methods Consecutive patients with surgical Stage I–III colon and rectosigmoid cancer who underwent curative resection between January 2003 and ...
Akira Ouchi, Kozo Kataoka, Eiji Shinto, Takashi Akiyoshi, Takefumi Yoshida, Yasuyuki Takamizawa, Yukihide Kanemitsu, Hirotoshi Kobayashi, Hideki Ueno, on behalf of the Lymph Nodes Committee of JSCCR   +9 more
wiley   +1 more source

Janus kinase 2 inhibition by pacritinib as potential therapeutic target for liver fibrosis

Hepatology, EarlyView., 2022
Diagram of the activation of the profibrotic and procontractile Janus kinase 2 (JAK2)/Ras homolog family member A/Rho‐kinase pathway and the inhibition of phosphorylated JAK2 by pacritinib to inhibit hepatic stellate cell activity. Abstract Background and Aims Janus kinase 2 (JAK2) signaling is increased in human and experimental liver fibrosis with ...
Sandra Torres, Cristina Ortiz, Nadine Bachtler, Wenyi Gu, Leon D. Grünewald, Nico Kraus, Robert Schierwagen, Christoph Hieber, Caroline Meier, Olaf Tyc, Maximilian Joseph Brol, Frank Erhard Uschner, Bart Nijmeijer, Christoph Welsch, Marie‐Luise Berres, Carmen Garcia‐Ruiz, Jose Carlos Fernandez‐Checa, Christian Trautwein, Thomas J. Vogl, Stefan Zeuzem, Jonel Trebicka, Sabine Klein   +21 more
wiley   +1 more source

Inflammation in cancer: therapeutic opportunities from new insights

Molecular Cancer
As one part of the innate immune response to external stimuli, chronic inflammation increases the risk of various cancers, and tumor-promoting inflammation is considered one of the enabling characteristics of cancer development.
Yifei Xie, Fangfang Liu, Yunfei Wu, Yuer Zhu, Yanan Jiang, Qiong Wu, Zigang Dong, Kangdong Liu   +7 more
doaj   +1 more source

Potential Survival Benefit of Neoadjuvant Docetaxel, Cisplatin and 5‐Fluorouracil Therapy in Patients With Esophageal Squamous Cell Carcinoma With Multiple Lymph Node Metastases: A Single‐Institute Propensity Score Analysis

Annals of Gastroenterological Surgery, EarlyView.
Although neoadjuvant chemotherapy with fluorouracil, cisplatin, and docetaxel (NAC‐DCF) is the current standard neoadjuvant regimen for esophageal squamous cell carcinoma, its substantial toxicity underscores the need to identify patients who derive the greatest benefit.
Eiji Higaki, Tetsuya Abe, Hironori Fujieda, Shigenori Kadowaki, Tsutomu Tanaka, Masahiro Tajika, Koji Komori, Seiji Ito, Isao Oze, Kei Muro   +9 more
wiley   +1 more source

Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis

Hepatology, EarlyView., 2022
Interleukin‐18 signaling promotes activation of hepatic stellate cells in mouse liver fibrosis. Abstract Background and Aims Nucleotide‐binding oligomerization domain‐like receptor‐family pyrin domain‐containing 3 (NLRP3) inflammasome activation has been shown to result in liver fibrosis.
Jana Knorr, Benedikt Kaufmann, Maria Eugenia Inzaugarat, Theresa Maria Holtmann, Lukas Geisler, Jana Hundertmark, Marlene Sophia Kohlhepp, Laela M. Boosheri, Daisy R. Chilin‐Fuentes, Amanda Birmingham, Kathleen M. Fisch, Joel D. Schilling, Sven H. Loosen, Christian Trautwein, Christoph Roderburg, Münevver Demir, Frank Tacke, Hal M. Hoffman, Ariel E. Feldstein, Alexander Wree   +19 more
wiley   +1 more source

Clinical Significance of PD‐L1 and HLA Expression in Esophageal Squamous Cell Carcinoma in Response to Immunotherapy

Annals of Gastroenterological Surgery, EarlyView.
This study evaluated immune‐related biomarkers in esophageal squamous cell carcinoma treated with immune checkpoint inhibitors after postoperative recurrence. PD‐L1 expression in tumor‐associated macrophages and tumor cells, together with HLA class I downregulation and HLA‐DR expression, were associated with favorable responses to immunotherapy.
Kosuke Kanemitsu, Yoshiyuki Tagayasu, Yoshihiro Komohara, Cheng Pan, Rin Yamada, Yukio Fujiwara, Kazuto Harada, Keisuke Kosumi, Yoshifumi Baba, Masaaki Iwatsuki   +9 more
wiley   +1 more source